Anna McGlothlin
A5081459172- COVID-19 Clinical Research Studies
- Statistical Methods in Clinical Trials
- Sepsis Diagnosis and Treatment
- Vitamin C and Antioxidants Research
- Long-Term Effects of COVID-19
- Amyotrophic Lateral Sclerosis Research
- SARS-CoV-2 and COVID-19 Research
- Vitamin K Research Studies
- Optimal Experimental Design Methods
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Intensive Care Unit Cognitive Disorders
- Antimicrobial Resistance in Staphylococcus
- Venous Thromboembolism Diagnosis and Management
- Lymphoma Diagnosis and Treatment
- Meta-analysis and systematic reviews
- Advanced Causal Inference Techniques
- Antifungal resistance and susceptibility
- Advanced Multi-Objective Optimization Algorithms
- Glioma Diagnosis and Treatment
- Traumatic Brain Injury and Neurovascular Disturbances
- Cancer Treatment and Pharmacology
- Neutropenia and Cancer Infections
- Statistical Methods and Inference
- Biosimilars and Bioanalytical Methods
Berry & Associates (United States)
2014-2025
University of Michigan
2024
University of Pittsburgh
2024
Indiana University – Purdue University Indianapolis
2024
Memorial Hospital
2024
Neurological Surgery
2024
Association Clinique et Thérapeutique Infantile du Val de Marne
2022-2023
Medical Research Institute of New Zealand
2023
University of Auckland
2023
Middlemore Hospital
2023
The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.We evaluated tocilizumab and sarilumab an ongoing international, multifactorial, adaptive platform trial. Adult Covid-19, within 24 hours after starting organ support the intensive care unit (ICU), were randomly assigned to receive (8 mg per kilogram body weight), (400 mg), or standard (control). primary outcome was respiratory cardiovascular support-free days, on...
There is broad interest in improved methods to generate robust evidence regarding best practice, especially settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale design of a large, international trial that combines features adaptive platform trials with pragmatic point-of-care determine treatment strategies for patients admitted an intensive care unit severe community-acquired pneumonia. The uses novel design, entitled...
Sepsis is a common syndrome with substantial morbidity and mortality. A combination of vitamin C, thiamine, corticosteroids has been proposed as potential treatment for patients sepsis.To determine whether hydrocortisone every 6 hours increases ventilator- vasopressor-free days compared placebo in sepsis.Multicenter, randomized, double-blind, adaptive-sample-size, placebo-controlled trial conducted adult sepsis-induced respiratory and/or cardiovascular dysfunction. Participants were enrolled...
Abstract Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and sarilumab an ongoing international, multifactorial, adaptive platform trial. Adult Covid-19, within 24 hours commencing organ support intensive care unit, were randomized to receive either (8mg/kg) or (400mg) standard (control). primary outcome was ordinal scale combining in-hospital mortality (assigned −1)...
BackgroundTrials of surgical evacuation supratentorial intracerebral hemorrhages have generally shown no functional benefit. Whether early minimally invasive removal would result in better outcomes than medical management is not known.MethodsIn this multicenter, randomized trial involving patients with an acute hemorrhage, we assessed the hematoma as compared management. Patients who had a lobar or anterior basal ganglia hemorrhage volume 30 to 80 ml were assigned, 1:1 ratio, within 24 hours...
Platelets represent a potential therapeutic target for improved clinical outcomes in patients with COVID-19.
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning /...
Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with 90-day mortality of 15%-30%. Despite this, <3000 people have been randomized into clinical trials treatments for SAB infection. The limited evidence base partly results from infections being difficult to complete at scale using traditional trial methods. Here we provide the rationale framework an adaptive platform applied infections. We detail design features Network Adaptive Platform (SNAP)...
<h3>Importance</h3> The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-CoV-2 Delta variant. <h3>Objective</h3> To evaluate mAb against variant compared no treatment ascertain comparative sotrovimab. <h3>Design, Setting, Participants</h3> This study comprised 2 parallel studies: (1) a propensity score–matched cohort vs (2) randomized trial consisted who received at University...
The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.
Sepsis accounts for 30% to 50% of all in-hospital deaths in the United States. Other than antibiotics and source control, management strategies are largely supportive with fluid resuscitation respiratory, renal, circulatory support. Intravenous vitamin C conjunction thiamine hydrocortisone has recently been suggested improve outcomes patients sepsis a single-center before-and-after study. However, before this therapeutic strategy is adopted, rigorous assessment its efficacy needed. The...
<h3>Importance</h3> Monoclonal antibody (mAb) treatment decreases hospitalization and death in high-risk outpatients with mild to moderate COVID-19; however, only intravenous administration has been evaluated randomized clinical trials of treatment. Subcutaneous may expand outpatient capacity qualified staff available administer treatment, but the association patient outcomes is understudied. <h3>Objectives</h3> To evaluate whether subcutaneous casirivimab imdevimab associated reduced 28-day...
Background/Aims: Response adaptive randomization has many polarizing properties in two-arm settings comparing control to a single treatment. The generalization of these features the multiple arm setting been less explored, and existing comparisons literature reach disparate conclusions. We investigate several generalizations response methods relating allocation trials, exploring how critiques generalize setting. Methods: perform simulation study schemes within randomization, designs on...
Abstract Background The use of adjunctive antibiotics directed against exotoxin production in Staphylococcus aureus bacteremia (SAB) is widespread, and it recommended many guidelines, but this based on limited evidence. Existing guidelines are the theoretical premise toxin suppression, as strains S. produce toxins such leukocidins (eg, Panton-Valentine leukocidin, toxic shock syndrome 1, exfoliative toxins, various enterotoxins). Many clinicians therefore believe that limiting release by...
There is a recognized unmet need for clinical trials to provide evidence-informed care infants, children and adolescents. This Special Communication outlines the capacity of 3 distinct trial design strategies, sequential, parallel, unified adult-pediatric bayesian adaptive design, incorporate into transform this current state evidence inequity. A whole-of-life demonstrated through Staphylococcus aureus Network Adaptive Platform (SNAP) trial.
673 Background: Pamrevlumab (Pam) is a fully human recombinant monoclonal antibody against connective tissue growth factor. Early clinical data with Pam plus chemotherapy showed favorable safety profile and potential efficacy in PDAC. In PrP, + GA was tested as first line (Line 1) second 2) therapy for mPDAC vs GA. PrP phase 2/3, innovative Bayesian adaptive platform trial sponsored by the Pancreatic Cancer Action Network testing multiple experimental arms efficiently common controls (1)....
Importance The etiology of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, is unknown. However, neuroinflammation and complement activation may play role in disease progression. Objective To determine the effects zilucoplan, an inhibitor C5, individuals with ALS. Design, Setting, Participants Zilucoplan was tested as regimen A HEALEY ALS Platform Trial, phase 2 to 3 multicenter, randomized, double-blind, placebo-controlled perpetual platform clinical trial sharing...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning /...